

Flerie provides update on portfolio company Provell Pharmaceuticals

Stockholm, Sweden, April 3 2025. Flerie AB announces that its portfolio company Provell Pharmaceuticals has filed for bankruptcy in the U.S. under a Chapter 7 proceeding. This does not affect Flerie's net asset value, as the company has previously written off the entire value of its holding in Provell Pharmaceuticals. Flerie's ownership in Provell Pharmaceuticals – a privately owned U.S. based specialty pharmaceutical company – amounts to 72%.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[Flerie provides update on portfolio company Provell Pharmaceuticals](#)